Leading biotechnology company focused on progressing psychedelic therapeutics Cybin Inc (OTCQB:CLXPF) on July 21st, 2021 announced receiving conditional listing approval from the New York Stock exchange.
Doug Drysdale, Cybin’s CEO added that the conditional listing approval on the stock exchange is a milestone for the firm’s growth journey and expects expanded access to investors fuelling the psychedelic therapeutics for patients suffering from mental health conditions.
The Company intends to keep the listing on NEO Exchange and has reserved the ticker CYBN on NYSE.CybinInc also announced filing its 13th new provisional patent application and moved with build-out of its digital therapeutics strategy.
Cybin is moving its programs beyond the psychedelic molecule, in an eco-system which might drive better patient treatments.
The firm has started next phase of its digital therapeutics platform enabling evaluation of patient outcomes through patient-centered data analytics platform. Its platform adds extra dimension to the firm’s development programs. It aims to harness cutting-edge technologies for supporting drug development candidates that would be a priority for company as well as industry.
Cybin’s recent collaboration with Kernel (quantitative neuroimaging technology), Greenbrook TMS and progression of other proprietary tools like EMBARK psychotherapy model, is allowing it build an advanced eco-system driving innovation from the psychedelic molecule.
Market Reaction:
On Wednesday, CLXPF stock gained 3% at $2.83 with more than 453k shares, compared to its average volume of 590k shares. The stock had moved within a range of $2.7240 – 2.9100 after opening the trade at $2.76. Over the past 52-week, the stock has been trading within a range of $0.0780 – 3.0100.
 Stock Doubled This Year: How Far Can it Go?){kind=link}